Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples

Acta Pharmacologica Sinica

Volumn 29, Issue 3, 2008, Pages 364-370

  Tsui, Ke Hung ^a   Juang, Horng Heng ^a   Lee, Tsong Hai ^a   Chang, Phei Lang ^a   Chen, Chien Lun ^a   Yung, Benjamin Yat Ming ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bladder carcinoma recurrence; Immunohistochemistry; Nucleophosmin B23

Indexed keywords

NUCLEOPHOSMIN;

ADULT; ADVANCED CANCER; ARTICLE; BLADDER CANCER; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 39849105855     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00747.x     Document Type: Article

References (20)

1. 1 Partin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics. CA Cancer J Clin 2005 ; 55: 74–108.
2. 2 Heney N, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder: progression and recurrence. J Urol 1983 ; 130: 1983–6.
3. 3 Hsu ZY, Yung BYM. Down‐regulation of nucleophosmin/B23 during retinoic acid‐induced differentiation of human promyelocytic leukemia HL‐60 cells. Oncogene 1998 ; 16: 915–23.
4. 4 Liu WH, Yung BYM. Mortalization of human promyelocytic leukemia HL‐60 cells to be more susceptible to sodium butyrate‐induced apoptosis and inhibition of telomerase activity by down‐regulation of nucleophosmin/B23. Oncogene 1998 ; 17: 3055–64.
5. 5 Feuerstein N, Spiegel S, Mond JJ. The nuclear matrix protein, numatrin (B23), is associated with growth factor induced mitogenesis in Swiss 3T3 fbroblasts and with T lymphocyte proliferation stimulated by lectins and anti‐T cell antigen receptor antibody. J Cell Biol 1988 ; 107: 1629–42.
6. 6 Tsui KH, Cheng AJ, Chang PL, Pan TL, Yung BYM. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma. Urology 2004 ; 64: 839–44.
7. 7 Sobin LH, Wittekind CH. Urinary bladder. In Sobin LH, editor. TNM classification of malignancy tumors, v5. 5th ed. New York: Wiley—Liss ; 1977. p 187–9.
8. 8 Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. In: Mostof FK, editor. International classification of tumors, No. 10. Geneva: World Health Organization, 1973.
9. 9 Suash S, Mehar CS, Deepak KG, Chitra S. Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol 2006 ; 79: 19–30.
10. 10 Raghaven D, Shipley WU, Garnick MB, Rusell PJ, Richie JP. Biology and management of bladder cancer. N Engl J Med 1990 ; 322: 1129–38.
11. 11 Ramakumar S, Bhuiyan J, Besse JA, Rusell PJ, Richie JP. Comparison of screening methods in the detection of bladder cancer. J Urol 1999 ; 161: 388–94.
12. 12 Tsui KH, Chen SM, Wang TM, Juang HH, Chen CL, Sun GH, et al. Comparison of voided urine cytology, nuclear matrix protein‐22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China. Asian J Androl 2007 ; 9: 711–5.
13. 13 Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M. The association of death‐associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002 ; 62: 4048–53.
14. 14 Sidransky D, Von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991 ; 252: 706–9.
15. 15 Parmar MK, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and followup polices in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol 1989 ; 142 (2 Pt 1): 284–8.
16. 16 Morris SB, Gordon EM, Shearer RJ, Woodhouse CR. Superficial bladder cancer: for how long should a tumor‐free patient have check cystoscopies Br J Urol 1995 ; 75: 193–6.
17. 17 Millan‐Rodriguez F, Chechile‐Toniolo G, Salvador‐Bayarri J, Palou J, Algaba F. Primary Superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000 ; 164: 680–4.
18. 18 Inouye CJ, Seto E. Relief of YY1‐induced transcriptional repression by protein‐protein interaction with the nucleolar phosphoprotein B23. J Biol Chem 1994 ; 269: 6506–10.
19. 19 Valdez BC, Perlaky L, Henning D, Saijo Y, Chan PK, Busch H. Identification of the nuclear and nucleolar localization signals of the protein p120: interaction with translocation protein B23. J Biol Chem 1994 ; 269: 23 776–83.
20. 20 Kondo T, Minamino N, Nagamura‐Inoue T, Matsumoto M, Taniguchi T, Tanaka N. Identification and characterization of nucleophosmin/B23/numatrin which binds the anti‐oncogenic transcription factor IRF‐1 and manifests oncogenic activity. Oncogene 1997 ; 15: 1275–81.